Table 1 Characteristics of serogroup B meningococcal strains used as target strains in SBA.

Strain	Serogroup	Year of isolation	Country	Clonal complex	Sequence type	fHbp	nadA	NHBA	PorA VR1	PorA VR2	mAb L3,7,9^a
NZ98/254	B	1998	NZL	41/44	42	1.14	Absent	2^b	7-2^b	4^b	+
M10837	B	2003	USA	41/44	409	2.19	Absent	2^b	18-1	34	−
LNP24651	B	2008	FRA	32	32	2.21	Yes (1)	47	7	16-26	+
M08389	B	2001	USA	162	162	2.21	Absent	20	22	14	+
M08117	B	2001	USA	41/44	437	2.19	Absent	29	7–4	1	+
MC58	B	1985	UK	32	74	1.1^b	Yes (1)	3	7	16-2	+
M09662	B	2002	USA	60	60	1.13	Absent	191	21	16	+
M14569	B	2005	USA	35	35	2.16	Absent	21	22-1	14	+
M09929	B	2002	USA	35	3592	2.16	Absent	19	12-1	16	+
M07576	B	2000	USA	35	35	2.16	Absent	21	22-1	14	−
M12898	B	2004	USA	35	35	2.16	Absent	143	5-1	2–2	+
M07 241084	B	2007	UK	41/44	1097	2.302	Absent	31	19	15	+

NZL New Zealand, USA United States of America, FRA France, UK United Kingdom, fHbp Factor H binding protein, nadA gene Neisseria adhesin A, NHBA Neisseria heparin binding antigen, PorA Porin A, VR variable region.
The main characteristics of the isolates and the vaccine antigen genotype profile are listed.
^aRecognition of the immunotype-specific mAb L3,7,9 is assessed via western blot on total cell extracts (Supplementary Fig. 1).
^bIndicates when the isolate expresses variants of fHbp, NHBA and PorA homologous to those contained in the 4CMenB vaccine (fHbp variant 1.1, NadA variant 3, NHBA peptide 2, and PorA P1.7-2,4 serosubtype).

Quick links

Search